Skip to main content
Equibles

Avidity Partners Management LP

Position in GPCR — Structure Therapeutics Inc.

CIK 1791827 DALLAS, TX
Back to GPCR Full portfolio

Position in GPCR

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$5,259,660
+$2,946,060 QoQ
Shares Held
98,000
+104.2% QoQ
Ownership
0.137%
of shares outstanding
% of Portfolio
0.84%
of 13F equity value
Holder Rank
#57
of 190 holders
Holding Since
Jun 2023
8 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in GPCR Over Time

Shares Held

Position Value (USD)

Derivatives in GPCR

reported options exposure · as of Mar 31, 2024
CallValue
$6,429,000
CallShares
150,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Avidity Partners Management LP holds $524,784,316 across 27 Biotechnology names. GPCR ranks #11 (1.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 DNTH
Dianthus Therapeutics, Inc. /DE/
 2,104,184 $205,115,856
2 CGON
CG Oncology, Inc.
 1,398,948 $99,395,255
3 ORKA
Oruka Therapeutics, Inc.
 760,424 $72,369,552
4 JBIO
Jade Biosciences, Inc.
 1,700,708 $37,789,731
5 ELVN
Enliven Therapeutics, Inc.
 550,000 $27,912,500
6 AKTS
Aktis Oncology, Inc.
 484,200 $15,605,766
7 PVLA
Palvella Therapeutics, Inc.
 70,000 $10,697,400
8 IMUX
Immunic, Inc.
 669,941 $10,296,993

All Filings in GPCR

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $5,259,660 98,000
2026-03-31 $2,313,600 48,000
2024-09-30 $18,912,201 430,900
2024-06-30 $42,215,250 1,075,000
2024-03-31 $6,429,000 150,000
2024-03-31 $37,031,040 864,000
2023-12-31 $24,456,000 600,000
2023-12-31 $44,020,800 1,080,000
2023-09-30 $25,210,000 500,000
2023-06-30 $1,571,346 37,800